Cargando…

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis

OBJECTIVE: To conduct a network meta-analysis of randomised controlled trials to determine the optimal clinical choice of first-line therapy for patients with ALK receptor tyrosine kinase (ALK) gene rearrangement non-small cell lung cancer (NSCLC). METHODS: Clinical trials in patients with histologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Jiahao, Zheng, Chuangjie, Zhang, Cuifen, Zhou, Ling, Liu, Zeyu, Zhou, Yanqun, Huang, Xuewu, Lin, Lizhu, Zhai, Linzhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Meta Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676299/ https://www.ncbi.nlm.nih.gov/pubmed/36380511 http://dx.doi.org/10.1177/03000605221132703

Ejemplares similares

Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis
por: Zhang, Xia, et al.
Publicado: (2017)

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
por: Samacá-Samacá, Daniel, et al.
Publicado: (2023)

Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis
por: Wen, Yaokai, et al.
Publicado: (2022)

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
por: Zhang, Cuifen, et al.
Publicado: (2023)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Development and External Validation of a Nomogram to Predict Cancer-Specific Survival in Patients with Primary Intestinal Non-Hodgkin Lymphomas
por: Zhang, Cuifen, et al.
Publicado: (2021)

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
por: Wenfan, Fu, et al.
Publicado: (2023)

Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis
por: Chen, Yifei, et al.
Publicado: (2017)

The impact of surgery on long-term survival of patients with primary intestinal non-Hodgkin lymphomas based on SEER database
por: Zhang, Cuifen, et al.
Publicado: (2021)

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
por: Ridouane, Yassine, et al.
Publicado: (2017)

Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer
por: Wu, Dong-Mei, et al.
Publicado: (2017)

First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis
por: Cheng, Ji, et al.
Publicado: (2019)

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
por: Kim, Bum Jun, et al.
Publicado: (2017)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of Twist overexpression in NSCLC
por: Li, Meng, et al.
Publicado: (2018)

Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
por: Han, Yue, et al.
Publicado: (2021)

First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
por: Fong, Khi Yung, et al.
Publicado: (2022)

First-line therapeutic strategy for patients with advanced non–small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
por: Chen, Chongxiang, et al.
Publicado: (2022)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
por: Petersohn, Svenja, et al.
Publicado: (2023)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis
por: Zhou, Mingyi, et al.
Publicado: (2017)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
por: Lin, Liping, et al.
Publicado: (2017)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

The efficacy and safety of first-line therapies for preventing chronic post-surgical pain: a network meta-analysis
por: Ning, Jie, et al.
Publicado: (2017)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
por: Zou, Shu-Peng, et al.
Publicado: (2022)

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis
por: Vogel, Arndt, et al.
Publicado: (2023)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer
por: Zhao, Hua-Ye, et al.
Publicado: (2016)

Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
por: Ren, Yuan-Rong, et al.
Publicado: (2015)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis
por: Zhang, Zhen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iamqbmqdk9lums4nug9t7hcjol